Vaccination Against Varicella: What's the Point?
Live attenuated varicella vaccine was developed in Japan in the early 1970 s as a means to prevent varicella primary infection with varicella-zoster virus (VZV) in healthy and immunocompromised individuals (Takahashi et al., 1974). Takahashi had attenuated the virus by passage in various cell cultures using different propagation temperatures and produced a candidate vaccine virus that proved to be both safe and immunogenic. Initially, there was great controversy as to whether it was likely to be safe to develop a vaccine that had the potential to become latent after immunization and that might even be oncogenic (Brunell, 1977, 1978). It was also questioned as to whether varicella was a serious enough disease to be worth preventing.
KeywordsLeukemia Defend Measle Rubella
- Centers-for-Disease-Control. (1996). Prevention of varicella: Recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb Mort Wkly Rep, (45), 1–36.Google Scholar
- Gershon, A., Takahashi, M., & Seward, J. (2008). Live attenuated varicella vaccine. In: S. Plotkin, W. Orenstein, & P. Offit (Eds.) Vaccines. pp. 915–958, Philadelphia: WB Saunders.Google Scholar
- Provost, P., Krah, D., Miller, W. et al. (1989). Comparative sensitivities of assays for antibodies induced by live varicella vaccine. Interscience Conference on Antimicrobial Agents and Chemotherapy.Google Scholar
- Shinefield, H., Black, S., Thear, M. et al. (2006). Safety and immunogenicity of a measles, mumps, rubella and varicella vaccine given with combined Haemophilus influenzae type b conjugate/hepatitis B vaccines and combined diphtheria-tetanus-acellular pertussis vaccines. Pediatr Infect Dis J, (25), 287–292.PubMedCrossRefGoogle Scholar